Advances in immune neoadjuvant/adjuvant therapy‐related adverse events of non‐small cell lung cancer

Abstract Lung cancer has been the leading cause of cancer‐related death for decades and years. For the patients with early stage non‐small cell lung cancer, surgical resection is the mainstay of therapy. Treatment before and after surgery, such as chemotherapy, can bring benefit to these patients, improving the 5 years survival rate by 5% approximately. Recently, the advent of immunotherapy significantly improved prognosis for the patient with lung cancer. Programmed death 1 and its ligand have become a powerful treatment option for lung cancer. In this review, we will discuss the role immunotherapy played in preoperative neoadjuvant and postoperative adjuvant treatment in lung cancer.